News & Updates

Show Multimedia Only
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer

High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer

15 Jan 2022

In patients with clinically localized Gleason 9–10 prostate cancer, dose-escalated radiotherapy confers better biochemical disease-free survival and prostate cancer-specific mortality than conventional doses, a recent study has found.

High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer

15 Jan 2022
Interval between biopsy and RARP does not impact biochemical recurrence in prostate cancer

Interval between biopsy and RARP does not impact biochemical recurrence in prostate cancer

28 Dec 2021